Commentary · 8 Apr 2026
Research articlePublished 17 May 2024
The Efficacy of Shenyankangfu Tablets Combined With Losartan Potassium for Chronic Glomerulonephritis: A Systematic Review and Meta-Analysis
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Objective: To conduct a systematic review of the efficacy and safety of Shenyankangfu tablets combined with losartan potassium in the treatment of chronic glomerulonephritis. Method: Through searching CNKI, VIP, Wanfang, Chinese Biomedical Literature Service System, American Clinical Trial Registry, Embase, Web of Science, PubMed, and Cochrane Library databases. The retrieval time was from the establishment of the database to June 1, 2023. All the Randomized Controlled Trials (RCTS) of Shenyankangfu tablets combined with losartan potassium in the treatment of renal chronic glomerulonephritis were collected, and the data of clinical studies meeting the inclusion criteria was extracted. Meta-analysis was performed using Review Manager 5.4 software. The study was registered with PROSPERO, CRD42024499186. Results: A total of 480 relevant literature was retrieved, and 25 eligible randomized controlled trials were selected, for a total of 2050 participants, including 1025 in the observation group and 1025 in the control group. The results of Meta-Analysis showed: Compared with losartan potassium alone in the treatment of chronic glomerulonephritis, Shenyankangfu tablets combined with losartan potassium can improve the clinical effective rate [RR=1.26, 95% CI (1.20, 1.31) , P<0.001].The reductions of blood urea nitrogen [MD=-0.78, 95% CI (-1.03, -0.53), P<0.001], blood creatinine [MD=-5.06, 95% CI (-8.01, -2.12), P<0.001], 24-hour urine protein quantification [MD=-0.51, 95% CI (-0.63, -0.40), P<0.001], urinary NAG enzyme [MD=-6.77, 95% CI (-12.03,-1.51), P<0.001] and the incidence of adverse reactions [RR=0.59, 95% CI (0.36, 0.95), P<0.001] were better than losartan potassium alone, and the difference was statistically significant. Conclusion: Shenyankangfu tablets combined with losartan potassium can improve the clinical treatment efficiency of chronic glomerulonephritis, and can effectively reduce the occurrence of blood urea nitrogen, blood creatinine, 24-hour urine protein quantification, urinary NAG enzyme, and adverse reactions.
Subjects
ToxicologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Clinical Toxicology.
Perspective · 25 Feb 2026
Toxicological and Health Effects: Mechanisms, Exposure Routes and Prevention Strategies
Case report · 23 Feb 2026
Case Report: Methaemoglobinaemia Following Indoxacarb Ingestion
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Clinical Toxicology
- SubjectToxicology
- BylineArticles whose byline prints “Yang Yang”
- BylineArticles whose byline prints “Jiahui Jin”
- BylineArticles whose byline prints “Yaxin Gao”
- BylineArticles whose byline prints “Dandan Zhu”
- BylineArticles whose byline prints “Heting Zhang”
- BylineArticles whose byline prints “Yuqing Xue”
- BylineArticles whose byline prints “Hongwu Wang”
- BylineArticles whose byline prints “Tieniu Zhao”
